Mollie's Fund : Episode 2

Video

Misconceptions About Melanoma

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Clinical trials should be designed to ease travel and financial burdens by using local care, telehealth and remote tools, Kimberly Demirhan explained.
Image of man with text.
Image of patient and doctor.
Image of Dr. Doug
Immune Therapy Expands Melanoma Treatment to More Patients
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
Image of a smiling woman with brown hair.
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Related Content
Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without extra side effects: © stock.adobe.com.
August 2nd 2025

New Treatment Combo Improves Advanced Melanoma Outcomes

Spencer Feldman
Adding SCIB1 or iSCIB1+ to standard treatments helped more patients with advanced melanoma respond and live longer without extra side effects.
CURE Cancer Horizons logo
August 2nd 2025

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of man with text.
August 2nd 2025

High-Fiber Diet Linked to Better Treatment Responses in Skin Cancer

Ryan Scott
Patients with skin cancer who were fed a high-fiber diet showed better response rates to treatment and longer event-free survival, according to data from the DIET trial.
Top Cancer Headlines from 2023
August 2nd 2025

Top Cancer Headlines from 2023

Alex Biese Brielle Benyon
From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.
Image of man with text.
August 2nd 2025

Refining Treatment Approaches and Advancements in High-Risk Melanoma

Ryan Scott
Dr. Vincent Ma discussed the most recent and notable treatment updates for patients with high-risk and advanced melanoma.
A A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma: © stock.adobe.com.
August 2nd 2025

Real-World Data Supports Amtagvi’s Benefit in Advanced Melanoma

Spencer Feldman
A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.